tbuckley/cabot-search huggingface dataset:
Possible Roles of New Mutations Shared by Asian and American Zika Viruses
Authors: Shozo Yokoyama, William T. Starmer
Journal: Molecular Biology and Evolution (2016)

Originating in Africa, the Zika virus (ZIKV) has spread to Asia, Pacific Islands and now to the Americas and beyond. Since the first isolation in 1947, ZIKV strains have been sampled at various times in the last 69 years, but this history has not been reflected in studying the patterns of mutation accumulation in their genomes. Implementing the viral history, we show that the ZIKV ancestor appeared sometime in 1930-1945 and, at that point, its mutation rate was probably less than 0.2 × 10-3/nucleotide site/year and subsequently increased significantly in most of its descendants. Sustaining a high mutation rate of 4 × 10-3/site/year throughout its evolution, the Ancestral Asian strain, which was sampled from a mosquito in Malaysia, accumulated 13 mutations in the 3'-untranslated region of RNA stem-loops prior to 1963, seven of which generate more stable stem-loop structures and are likely to inhibit cellular antiviral activities, including immune and RNA interference (RNAi) pathways. The seven mutations have been maintained in all Asian and American strains and may be responsible for serious medical problems we are facing today and offer testable hypotheses to examine their roles in molecular interactions during brain development.
Gleevec as Therapy for CML Relapsed after Allogeneic Stem Cell Transplantation: High Rate of BCR-ABL PCR Negativity and Donor Graft Reconstitution.
Authors: Vaneuza A.M. Funke, Samir K. Nabhan, Michel M. Oliveira, Jefferson Ruiz, Daniela C. Setubal, Ana Paula Azambuja, Denise H. Lima, Terezinha K. Kojo, Henrique Bitencourt, Nelson Hamerschlak, Nelma Clementino, Heliz Regina A. Neves, Ricardo Pasquini
Journal: Blood (2006)
Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing
Authors: Lisa Giulino Roth, Kai Wang, Theresa MacDonald, Susan Mathew, YiFang Tam, Maureen T Cronin, Gary Palmer, Norma Lucena-Silva, Francisco Pedrosa, Marcia Pedrosa, Julie Teruya-Feldstein, Govind Bhagat, Bachir Alobeid, Lorenzo Leoncini, Cristiana Bellan, Emily Rogena, Mark A Rubin, Raul Ribeiro, Roman Yelensky, Wayne Tam, Philip Stephens, Ethel Cesarman
Journal: Blood (2012)
A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Authors: Raya Mawad, Pamela S. Becker, Paul C. Hendrie, Bart L Scott, Brent L. Wood, Carol Dean, Vicky Sandhu, H. Joachim Deeg, Roland B. Walter, Lixia Wang, Jack Singer, Elihu H. Estey, John Pagel
Journal: Blood (2014)
A Dual Role of Upper Zone of Growth Plate and Cartilage Matrix–Associated Protein in Human and Mouse Osteoarthritic Cartilage: Inhibition of Aggrecanases and Promotion of Bone Turnover
Authors: Michael Stock, Stefanie Menges, Nicole Eitzinger, Maria Geßlein, Renate Botschner, Laura Wormser, Alfiya Distler, Ursula Schlötzer‐Schrehardt, Katharina Dietel, Jörg Distler, Christian Beyer, Kolja Gelse, Klaus Engelke, Marije I. Koenders, Wim van den Berg, Klaus von der Mark, Georg Schett
Journal: Arthritis & Rheumatology (2017)

Objective Cartilage damage and subchondral bone changes are closely connected in osteoarthritis. Nevertheless, how these processes are interlinked is, to date, incompletely understood. This study was undertaken to investigate the mechanistic role of a cartilage‐derived protein, upper zone of growth plate and cartilage matrix–associated protein (UCMA), in osteoarthritis‐related cartilage and bone changes. Methods UCMA expression was assessed in healthy and osteoarthritic human and mouse cartilage. For analysis of cartilage and bone changes, osteoarthritis was induced by destabilization of the medial meniscus (DMM) in wild‐type (WT) and Ucma ‐deficient mice. UCMA–collagen interactions, the effect of UCMA on aggrecanase activity, and the impact of recombinant UCMA on osteoclast differentiation were studied in vitro. Results UCMA was found to be overexpressed in human and mouse osteoarthritic cartilage. DMM‐triggered cartilage changes, including increased structural damage, proteoglycan loss, and chondrocyte cell death, were aggravated in Ucma ‐deficient mice compared to WT littermates, thereby demonstrating the potential chondroprotective effects of UCMA. Moreover, UCMA inhibited ADAMTS‐dependent aggrecanase activity and directly interacted with cartilage‐specific collagen types. In contrast, osteoarthritis‐related bone changes were significantly reduced in Ucma ‐deficient mice, showing less pronounced osteophyte formation and subchondral bone sclerosis. Mechanistically, UCMA directly promoted osteoclast differentiation in vitro. Conclusion UCMA appears to link cartilage with bone changes in osteoarthritis by supporting cartilage integrity as an endogenous inhibitor of aggrecanases while also promoting osteoclastogenesis and subchondral bone turnover. Thus, UCMA represents an important link between cartilage and bone in osteoarthritis.
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk
Authors: Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. TO THE EDITOR: In their large epidemiological study, Joo et al.1 report on hepatitis B serum antigen seropositivity as a factor strongly associated with a reduced risk of developing nonalcoholic fatty liver disease (NAFLD) over follow‐up, probably as a result of interference of hepatitis B virus (HBV) with the pathogenesis of NAFLD. These findings also have major clinical consequences that we would like to address. A previous article by our group demonstrated the link between cirrhotic and noncirrhotic liver disease of varying etiology and cardiovascular risk.2 Based on published studies, we concluded that liver steatosis due to alcohol abuse, metabolic derangements, and hepatitis C virus (HCV) infection is indeed associated with insulin resistance and cardiovascular risk. Conversely, HBV infection and primary biliary cholangitis, which (except in the case of the concurrent host's additional metabolic risk factors) are not directly associated with liver steatosis and insulin resistance, appear to be spared from cardiometabolic risk.2 Moreover, with regard to the replicative cycle of HBV and HCV, liver steatosis seems to exert opposite influences: whereas HCV is associated with steatogenesis and thrives on fatty substrates, HBV is not steatogenic, and its replication seems to be inhibited by fatty liver.2 From this general notion, and given that liver steatosis is a strong predictor of cardiometabolic risk,3 it can be anticipated that HBV infection, being associated with lower rates of incident NAFLD, will likely be spared from cardiometabolic risk. Confirming this prediction, recent studies have shown that individuals with HBV infection are protected from developing both the metabolic syndrome and acute ischemic stroke.4 In conclusion, the study by Joo et al. is important in promoting our understanding of the pathogenesis and risk factors of NAFLD. However, additional studies are needed to further explore the link between liver steatosis, hepatotropic viruses, and cardiometabolic risk and to strengthen the notion that fatty liver is a trigger and an amplifier of cardiometabolic risk and a major modulator of infection with hepatotropic viruses.2
Leukoreduction to Prevent Alloimmune Platelet (Plt) Refractoriness in a Dog Transfusion Model: Types of Residual White Blood Cells (WBCs) Directly Affect Transfusion Outcomes.
Authors: Sherrill J. Slichter, Kraig Abrams, Lakshmi Gaur, Karen Nelson, Esther Pellham, Todd Christoffel
Journal: Blood (2004)
Reversal of Multidrug Resistance by Magnetic Fe3O4 Nanoparticle Copolymerizating Daunorubicin and mdr1-shRNA Expression Vetor in Leukemia Cells.
Authors: Bao-An Chen, Peipei Mao, Jian Cheng, Feng Gao, Jia-Hua Ding, Chong Gao, Wei Zhang, Cui-Rong Xu, Wen-Lin Xu, Xin-Chen Sun, Ning-Na Chen, Xiao-Mao Li, Xue-Mei Wang
Journal: Blood (2009)
Variant Creutzfeldt–Jakob Disease in a Patient with Heterozygosity at<i>PRNP</i>Codon 129
Authors: Tzehow Mok, Zane Jaunmuktane, Susan Joiner, Tracy Campbell, Catherine Morgan, Benjamin Wakerley, Farhad Golestani, Peter Rudge, Simon Mead, H Rolf Jäger, Jonathan D F Wadsworth, Sebastian Brandner, John Collinge
Journal: New England Journal of Medicine (2017)

In this case study, variant Creutzfeldt–Jakob disease (CJD) is shown to occur in a young man with heterozygosity, rather than homozygosity, at codon 129 of the prion protein gene (PRNP).
Identification and Functional Significance of Novel Type of Structurally Aberrant Transcripts of DCC In B-Cell Malignancies.
Authors: Hisao Nagoshi, Tomohiko Taki, Junya Kuroda, Kazuhiro Nishida, Minako Gotoh, Keiko Okuda, Satoru Kobayashi, Mio Yamamoto, Yasuhiko Tsutsumi, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Takemi Otsuki, Masafumi Taniwaki
Journal: Blood (2010)
Impact of Graft Source on Immune Recovery: Comparions Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.
Authors: Sarah Cooley, John E. Wagner, Claudio Brunstein, Mie Hagiwara, Giordi Orreggio, Julie Curtsinger, Todd Defor, Xianghua Luo, Bruce R. Blazar, Phillip McGlave, Jeffrey S. Miller, Michael R Verneris
Journal: Blood (2010)
High Incidence of Extramedullary Relapses Following Allogeneic Bone Marrow Transplant (Allo-BMT) in Adults with Acute Lymphoblastic Leukemia.
Authors: Ahmed Absi, Brian J. Bolwell, Ronald Sobecks, Brad Pohlman, Steve Andresen, Lisa Rybicki, Matt Kalaycio
Journal: Blood (2004)
Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM.
Authors: Richard A. Campbell, Haiming Chen, Hee Jin Lee, Howard S. Yeh, Melinda S. Gordon, Benjamin Bonavida, Shen Pang, Jonathan Said, James R. Berenson
Journal: Blood (2005)
Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy
Authors: Trevor J. Royce, Ming-Hui Chen, Jing Wu, Marian Loffredo, Andrew A. Renshaw, Philip W. Kantoff, Anthony V. D’Amico
Journal: JAMA Oncology (2017)

Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are surrogates for all-cause mortality, and how their performance compares, is unknown.To ascertain and compare the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PSA doubling time <9 months, and interval to PSA failure <30 months) for all-cause mortality using the proportion of treatment-effect metric.For this randomized clinical trial, 206 men with unfavorable-risk prostate cancer who were seen at a Harvard-affiliated academic hospital or an associated community hospital between December 1, 1995, to April 15, 2001, were identified, randomized to radiation therapy alone or radiation therapy followed by 6 months of androgen deprivation therapy, and followed for a median 16.62 years. This analysis looks at the subgroup of 157 men with minimal comorbidities or no comorbidity (median follow-up, 16.49 months).Patients were previously randomized to receive radiation therapy or radiation and 6 months of androgen deprivation therapy.Risk of all-cause mortality.Overall, a cohort of 157 men (median [interquartile range] age, 72.43 [68.75-75.53]) with unfavorable-risk prostate cancer and minimal or no comorbidities were selected for this study. Three tested metrics met all 4 Prentice criteria for surrogacy for the surrogate covariate in the adjusted model for all-cause mortality: PSA nadir greater than 0.5 ng/mL (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.17-2.52; P = .01), PSA doubling time less than 9 months (aHR, 2.06; 95% CI, 1.29-3.28; P = .003), and interval to PSA failure less than 30 months (aHR, 1.76; 95% CI, 1.06-2.92; P = .03); while PSA failure did not. For the 3 successful surrogates, the proportion of treatment effect values were 103.86%, 43.09%, and 41.26%, respectively.A PSA nadir value of greater than 0.5 ng/mL following radiation and androgen deprivation therapy appears to identify men prior to PSA failure who are at high-risk for death. This could be used to select men for entry at the time of PSA nadir onto randomized trials evaluating the impact on survival of salvage androgen deprivation therapy with or without agents shown to prolong survival in men with castrate-resistant metastatic prostate cancer.clinicaltrials.gov Identifier: NCT00116220.
Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation
Authors: Ho-Young Yhim, Kihyun Kim, Jin Seok Kim, Hye Jin Kang, Jeong-A Kim, Chang-Ki Min, Sung Hwa Bae, Eunkyung Park, Deok-Hwan Yang, Cheolwon Suh, Min Kyoung Kim, Yeung-Chul Mun, Hyeon Seok Eom, Ho Jin Shin, Hwi-Joong Yoon, Jung Hye Kwon, Jae Hoon Lee, Yang Soo Kim, Sung-Soo Yoon, Jae-Yong Kwak
Journal: Blood (2011)
Generation of T Cells of Desired HLA Restriction Specific for Epitopes of a Self-Antigen, WT1, for the Adoptive Immunotherapy of WT1 Positive Malignancies Using A Panel of Artificial Antigen Presenting Cells Expressing Prevalent HLA Alleles.
Authors: Ekaterina Doubrovina, Aisha Hasan, Banu Oflaz-Sozmen, Annamalai Selvakumar, Michel W Sadelain, Richard J O'Reilly
Journal: Blood (2009)
CD34+CD19−, CD34+CD19+ and CD34−CD19+ Cells May All Have Leukemia-Initiating Potential in NOD/Scid Mice.
Authors: Christoph Le Viseur, Marc Hotfilder, Annegret Rosemann, Ronald Stam, Andre Schrauder, Leonard Shultz, Martin Schrappe, Rob Pieters, Josef Vormoor
Journal: Blood (2006)
Mapping the Gene Expression Diversity Across Hematological and Lymphoid Malignancies
Authors: Thomas Liuksiala, Kirsi Granberg, Sergei Häyrynen, Juha Mehtonen, Petri Pölönen, Susanna Teppo, Jake Lin, Saara Laukkanen, Patrick May, Matti Nykter, Merja Heinäniemi, Olli Lohi
Journal: Blood (2015)
Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years)
Authors: Michele Pohlen, Christoph Groth, Tim Sauer, Dennis Görlich, Rolf Mesters, Christoph Schliemann, Georg Lenz, Carsten Müller-Tidow, Thomas Büchner, Wolfgang E Berdel, Matthias Stelljes
Journal: Blood (2015)
Incidence of Altered Biodistribution Detected by Indium 111 (111In) Imaging Prior to Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy: Results from a Zevalin Imaging Registry.
Authors: Peter Conti, Christine White, Peter Pieslor, Gene Menendez, V. Douglas Harrough, Dan Matso, Jacqueline Aussie, Thomas Ryskamp, Paul A. Foster
Journal: Blood (2004)
Soft robotic sleeve supports heart function
Authors: Ellen T. Roche, Markus A. Horvath, Isaac Wamala, Ali Alazmani, Sang-Eun Song, William Whyte, Zurab Machaidze, Christopher J. Payne, James C. Weaver, Gregory Fishbein, Joseph Kuebler, Nikolay V. Vasilyev, David J. Mooney, Frank A. Pigula, Conor J. Walsh
Journal: Science Translational Medicine (2017)

A soft robotic sleeve modeled on the structure of the human heart assists cardiovascular function in an ex vivo and in vivo porcine model of heart failure.
A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naïve prostate cancer patients with bone metastases: Results of ZAPCA study.
Authors: Tomomi Kamba, Toshiyuki Kamoto, Yousuke Shimizu, Shunichi Namiki, Kiyohide Fujimoto, Hiroaki Kawanishi, Fuminori Sato, Shintaro Narita, Takefumi Satoh, Hideo Saito, Mikio Sugimoto, Jun Teishima, Naoya Masumori, Shin Egawa, Hideki Sakai, Yusaku Okada, Toshiro Terachi, Osamu Ogawa
Journal: Journal of Clinical Oncology (2015)

150 Background: Zoledronic acid (ZA) is proved to be useful for the prevention of skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases, but its early use combined with androgen deprivation therapy (ADT) in men with hormonal treatment-naïve prostate cancer and bone metastases is controversial. Methods: A total of 227 men with hormonal treatment-naïve prostate cancer and bone metastases were randomly assigned in a 1:1 ratio to receive zoledronic acid (4mg intravenously every 4 weeks up to 2 years) along with ADT (LH-RH analogue + bicalutamide, MZ group) or ADT alone (MAB group). Stratification factors were PSA (&lt;200ng/ml vs. ≥200ng/ml), EOD (extent of diseases) grade (1,2 vs. 3,4) and Gleason score (&lt;7 vs. ≥8). The primary end point was time to treatment failure (TTTF), defined as 3 consecutive rise of PSA from the nadir, clinical progression, SRE, death or cessation of protocol therapy for any reason. Results: The median follow-up was 41.1 months. The median TTTF was 12.4 months in MZ group (95% CI, 10.6 to 16.6) and 9.7 months in MAB group (95% CI, 8.9 to 12.6; hazard ratio, 0.754; 95% CI, 0.567 to 1.003; log-rank P= .051). In a subset of men with baseline PSA levels &lt;200ng/mL, the median TTTF was 23.7 months in MZ group (95% CI, 15.2 to 31.3) and 9.8 months in MAB group (95% CI, 6.6 to 17.0; hazard ratio, 0.575; 95% CI, 0.354 to 0.933; log-rank P= .023). An exploratory multivariate analysis using Cox proportional hazards model identified MZ group, age less than 80, and EOD ≤2 as independent factors associated with better TTTF. Conclusions: In men with hormonal treatment naïve prostate cancer with bone metastases, concurrent use of ZA with ADT did not show a significant advantage over ADT alone regarding TTTF. However, in a subgroup of men with lower baseline PSA levels, ZA significantly prolonged TTTF, compared with ADT alone. Clinical trial information: NCT00685646.
Absence of Inhibitor Development in the Routine Clinical Use of Alphanate® in Patients with Severe Hemophilia A: Results From a Long-Term Post-Marketing Surveillance Study.
Authors: Charles L. Sexauer, Yasmin Ayob, Madeline Cantini, Miguel Antonio Escobar, Tamiko Fukuda, Kristine Holtz, Pier Manucci, Kathryn Moynihan, Kapil Saxena, Christopher Walsh, Antonio Páez, Paul P Pinciaro, Michael Ken Woodward
Journal: Blood (2009)
Blocking the Autophagy Gene 5 (ATG5) Impairs ATRA-Induced Myeloid Differentiation, and ATG5 Is Downregulated in AML
Authors: Adrian Britschgi, Shida Yousefi, Judith Laedrach, Deborah Shan, Hans-Uwe Simon, Andreas Tobler, Martin F. Fey, Mario P. Tschan
Journal: Blood (2008)
Prefibrotic Myelofibrosis (PreMF) Belongs to a Continuum of Epidemiological, Clinical and Histological Characteristics Featuring Primary Myelofibrosis (PMF)
Authors: Giovanni Barosi, Vittorio Rosti, Rita Campanelli, Paolo Catarsi, Antonina M. Isgrò, Letizia Lupo, Margherita Massa, Valentina Poletto, Gianluca Viarengo, Laura Villani, Umberto Magrini
Journal: Blood (2011)
MSX-122, an orally available small molecule targeting CXCR4, inhibits primary tumor growth in an orthotopic mouse model of lung cancer and improves the effect of paclitaxel
Authors: Yawei Zhang, Zhongxing Liang, Hui Wu, Aizhi Zhu, Younghyoun Yoon, Sijia Wang, Hyunsuk Shim
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

1190 

CXCR4 has been shown to play a critical role in the multiple steps of metastatic progression. Most importantly, it allows for homing of cancerous cells to distant organ sites, such as the lungs, bone, and liver, which contain high levels of CXCL12. Published results from numerous researchers, along with our own have demonstrated that blocking CXCR4 function can inhibit the spread of cancer cells to the lungs and bones. Studies have also suggestedthat the expression of CXCR4 by SCLC cells cooperates with integrinsthat regulate the adhesion of tumor cells to the marrow microenvironment and other sites of high CXCL12 expression,which in turn confers drug resistance and tumor cell growth. This supports further data showing that CXCR4/CXCL12 interactions induce Akt activation, which promotes tumor cell survival. Therefore, we hypothesized that enriched CXCL12 in the lung stromal environment promotes cell survival of CXCR4-positive lung cancer cells. We therefore sought to determine whether blocking CXCR4 signaling would inhibit primary tumor growth in lungs and, at the same time, sensitize tumor cells to conventional chemotherapy. We tested this hypothesis with MSX-122, an orally available small molecule, CXCR4 antagonist that was discovered in our labs at Emory University and has been licensed to Metastatix, Inc. for clinical development. The compelling features of MSX-122 include potent inhibition of the CXCR4/CXCL12 interaction, good tolerability in mice, rats, and monkeys at doses up to 600 mg/kg, and good plasma exposure after oral dosing that is suitable for once per day dosing in monkeys. Our data demonstrate that MSX-122 is a safe and highly effective agent for blocking cancer metastasis and tumor angiogenesis by antagonizing CXCR4. In order to evaluate whether targeting CXCR4 affects growth of lung cancer and increases the effects of chemotherapy, we intrabronchially implantedA549 human lung adenocarcinoma cells into nude mice. In this experiment, fourgroups of mice received respectively the treatment of MSX-122 alone, paclitaxel alone, combination of these two drugs, or vehicle staring on the 7th day aftertumor implantation. Mice were sacrificed on the 21st day after tumor implantation.Significant antitumor effects were observed in all three treated groups by qRT-PCR using primers for human housekeeping gene, HPRT. The antitumor effect was significantly better in the group treated with MSX-122 than in that with paclitaxel. This effect was further enhanced by the combination of MSX-122 and paclitaxel. This study suggests that the CXCR4 antagonist, MSX-122, may be an effective therapy for lung cancer, both as a single agent as well as in combination with paclitaxel.
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
Authors: Bram De Laere, Pieter-Jan van Dam, Tom Whitington, Markus Mayrhofer, Emanuela Henao Diaz, Gert Van den Eynden, Jean Vandebroek, Jurgen Del-Favero, Steven Van Laere, Luc Dirix, Henrik Grönberg, Johan Lindberg
Journal: European Urology (2017)
A Novel Perspective on Stem Cells, Tissue Senescence and Aging: Pluripotent Very Small Embryonic-Like Stem Cells (VSELs) and Hematopoietic Stem Cells (HSCs) Are Prematurely Depleted in Adult Bone Marrow (BM) in Response to Prolonged Growth Hormone/Insulin-Like Growth Factor-1 Signaling (IIS) and Chronic Increase in Caloric Uptake
Authors: Magda Kucia, Janina Ratajczak, Dong-Myung Shin, Rui Liu, Michal Masternak, Andrzej Bartke, Mariusz Z Ratajczak
Journal: Blood (2011)